妊娠期高血压疾病与胎儿生长受限的相关性研究

doi:10.12280/gjfckx.20200781

国际妇产科学杂志 ›› 2021, Vol. 48 ›› Issue (2): 182-185.doi: 10.12280/gjfckx.20200781

• 产科生理及产科疾病综述 • 上一篇下一篇

妊娠期高血压疾病与胎儿生长受限的相关性研究

李佳雯, 郑小敏, 应豪, 黄璐^△()

214002 南京医科大学附属无锡妇幼保健院妇产科（李佳雯,黄璐）,优生优育遗传医学研究所（郑小敏）;同济大学附属第一妇婴保健院（应豪）

收稿日期:2020-08-24 出版日期:2021-04-15 发布日期:2021-04-16
通讯作者: 黄璐 E-mail:huanglusz@163.com
基金资助:
江苏省妇幼保健重点人才项目(FRC201719);江苏省卫生健康委科研项目(LGY2018015)

Study on the Association between Hypertensive Disorders Complicating Pregnancy and Fetal Growth Restriction

LI Jia-wen, ZHENG Xiao-min, YING Hao, HUANG Lu^△()

Department of Obstetrics and Gynecology(LI Jia-wen, HUANG Lu), Institute of Prenatal and Postnatal Genetic Medicine (ZHENG Xiao-min), The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi 214002, Jiangsu Province, China; First Maternity and Infant Hospital Affiliated to Tongji University, Shanghai 200040, China (YING Hao)

Received:2020-08-24 Published:2021-04-15 Online:2021-04-16
Contact: HUANG Lu E-mail:huanglusz@163.com

摘要/Abstract

摘要：

妊娠期高血压疾病（hypertensive disorders complicating pregnancy,HDCP）是妊娠期特有的以妊娠和血压升高并存的一组疾病。该组疾病以高血压、蛋白尿、水肿为特征,可导致妊娠妇女心功能衰竭、子痫、产后出血或胎盘早剥等不良情况发生概率上升,并伴有全身多脏器的损害,严重影响母婴健康。胎儿生长受限（fetal growth restriction,FGR）是指胎儿因遗传或母体胎盘等环境因素影响而未达到其生长潜能。我国FGR的发生率为6.39%,是围生儿死亡的第二大原因。HDCP患者合并发生FGR的概率高达20%~30%,但两者关联的病理机制尚不明确。现有的研究普遍认为HDCP合并FGR可能受血管内皮生长因子（vascular endothelial growth factor,VEGF）、胎盘生长因子（placental growth factor,PlGF）、可溶性血管内皮生长因子受体1（soluble fms-like tyrosine kinase-1,sFlt-1）等多种细胞因子影响,与胎盘功能不全有关。

关键词: 高血压, 妊娠性, 胎儿生长受限, 胎儿发育, 血管内皮生长因子类, 胎盘生长因子, 可溶性血管内皮生长因子受体1, 胎盘

Abstract:

Hypertensive disorders complicating pregnancy(HDCP) is a group of diseases with pregnancy and high blood pressure at the same time, which is unique during the gestation period. This group of diseases are characterized by high blood pressure, proteinuria and edema. It can lead to higher risk of adverse conditions such as heart failure, eclampsia, postpartum hemorrhage or placental abruption in pregnant women. And it is also accompanied with multiple organ damage, affect mother and her baby′s health seriously. Fetal growth restriction (FGR) is a failure of fetus to reach its growth potential due to genetical or maternal placenta environmental factors. FGR is the second reason of perinatal death in China, with an incidence of 6.39%. The incidence of HDCP and FGR is high to 20%-30%, however, the pathological mechanism of the relationship between them is not clear. Existing studies generally believe that hypertension during pregnancy combined with fetal intrauterine growth restriction, may be affected by vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and many other cytokines, which are related to placental insufficiency.

Key words: Hypertension, pregnancy-induced, Fetal growth restriction, Fetal development, Vascular endothelial growth factors, Placenta growth factor, Soluble fms-like tyrosine kinase-1, Placenta

李佳雯, 郑小敏, 应豪, 黄璐. 妊娠期高血压疾病与胎儿生长受限的相关性研究[J]. 国际妇产科学杂志, 2021, 48(2): 182-185.

LI Jia-wen, ZHENG Xiao-min, YING Hao, HUANG Lu. Study on the Association between Hypertensive Disorders Complicating Pregnancy and Fetal Growth Restriction[J]. Journal of International Obstetrics and Gynecology, 2021, 48(2): 182-185.

参考文献 23

[1]	虞国芬, 王霓. 275例胎儿宫内生长受限高危因素的Logistic回归分析[J]. 中国妇幼保健, 2017,32(9):1929-1932. doi: 10.7620/zgfybj.j.issn.1001-4411.2017.09.37.
[2]	Rana S, Lemoine E, Granger JP, et al. Preeclampsia: Pathophysiology, Challenges, and Perspectives[J]. Circ Res, 2019,124(7):1094-1112. doi: 10.1161/CIRCRESAHA.118.313276. pmid: 30920918
[3]	Yuan T, Zhang T, Han Z. Placental vascularization alterations in hypertensive disorders complicating pregnancy (HDCP) and small for gestational age with HDCP using three-dimensional power doppler in a prospective case control study[J]. BMC Pregnancy Childbirth, 2015,15:240. doi: 10.1186/s12884-015-0666-1. doi: 10.1186/s12884-015-0666-1 pmid: 26437940
[4]	Wang Y, Liu LL, Tian Y, et al. Upregulation of DAPK2 ameliorates oxidative damage and apoptosis of placental cells in hypertensive disorder complicating pregnancy by suppressing human placental microvascular endothelial cell autophagy through the mTOR signaling pathway[J]. Int J Biol Macromol, 2019,121:488-497. doi: 10.1016/j.ijbiomac.2018.09.111. doi: 10.1016/j.ijbiomac.2018.09.111 pmid: 30243997
[5]	Osol G, Ko NL, Mandalà M. Plasticity of the Maternal Vasculature During Pregnancy[J]. Annu Rev Physiol, 2019,81:89-111. doi: 10.1146/annurev-physiol-020518-114435. doi: 10.1146/annurev-physiol-020518-114435 pmid: 30742784
[6]	赵虎, 张凌, 蔡一玲, 等. 妊娠期高血压疾病患者胎盘组织中VEGF与MMP-9表达水平与子痫前期病情的相关性[J]. 实用临床医药杂志, 2016,20(15):63-65. doi: 10.7619/jcmp.201615018.
[7]	陈益明, 卢莎, 顾琳媛, 等. 中孕期血清可溶性血管内皮生长因子受体1、胎盘生长因子水平及其比值筛查妊娠期高血压疾病的效率[J]. 中国卫生检验杂志, 2020,30(4):434-438.
[8]	Lecarpentier E, Zsengellér ZK, Salahuddin S, et al. Total Versus Free Placental Growth Factor Levels in the Pathogenesis of Preeclampsia[J]. Hypertension, 2020,76(3):875-883. doi: 10.1161/HYPERTENSIONAHA.120.15338. pmid: 32654553
[9]	Agrawal S, Cerdeira AS, Redman C, et al. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study[J]. Hypertension, 2018,71(2):306-316. doi: 10.1161/HYPERTENSIONAHA.117.10182. doi: 10.1161/HYPERTENSIONAHA.117.10182 pmid: 29229743
[10]	ACOG Practice Bulletin No. 204: Fetal Growth Restriction[J]. Obstet Gynecol, 2019,133(2):e97-e109. doi: 10.1097/AOG.0000000000003070. pmid: 30681542
[11]	Audette MC, Kingdom JC. Screening for fetal growth restriction and placental insufficiency[J]. Semin Fetal Neonatal Med, 2018,23(2):119-125. doi: 10.1016/j.siny.2017.11.004. pmid: 29221766
[12]	吴寒舒, 刘福林, 吴婉容, 等. 胎儿生长受限胎盘血管形成障碍的相关研究进展[J]. 武汉大学学报(医学版), 2017,38(3):512-516. doi: 10.14188/j.1671-8852.2017.03.037.
[13]	Cañas D, Herrera EA, García-Herrera C, et al. Fetal Growth Restriction Induces Heterogeneous Effects on Vascular Biomechanical and Functional Properties in Guinea Pigs (Cavia porcellus)[J]. Front Physiol, 2017,8:144. doi: 10.3389/fphys.2017.00144. doi: 10.3389/fphys.2017.00144 pmid: 28344561
[14]	Krishnan T, David AL. Placenta-directed gene therapy for fetal growth restriction[J]. Semin Fetal Neonatal Med, 2017,22(6):415-422. doi: 10.1016/j.siny.2017.04.005. doi: 10.1016/j.siny.2017.04.005 pmid: 28522033
[15]	李意, 蒋晓敏. 母体血清CXCL12、CXCR4、VEGF及PLGF的水平与子痫前期及其合并FGR的相关性研究[J]. 中国妇幼健康研究, 2020,31(2):247-251. doi: 10.3969/j.issn.1673-5293.2020.02.022.
[16]	Jiang Z, Zou Y, Ge Z, et al. A Role of sFlt-1 in Oxidative Stress and Apoptosis in Human and Mouse Pre-Eclamptic Trophoblasts[J]. Biol Reprod, 2015,93(3):73. doi: 10.1095/biolreprod.114.126227. pmid: 26203176
[17]	蒋玲玲, 刘曼华, 乔海风, 等. 孕妇血清HIF-1α、胎盘血流与胎儿生长受限的相关性研究[J]. 中国妇幼保健, 2017,32(15):3523-3526. doi: 10.7620/zgfybj.j.issn.1001-4411.2017.15.44.
[18]	张展, 宋婉玉, 张琳琳, 等. 血管生成因子、抗血管生成因子表达变化在子痫前期发病中的作用机制研究进展[J]. 山东医药, 2017,57(15):112-114. doi: 10.3969/j.issn.1002-266X.2017.15.035.
[19]	Youssef L, Miranda J, Paules C, et al. Fetal cardiac remodeling and dysfunction is associated with both preeclampsia and fetal growth restriction[J]. Am J Obstet Gynecol, 2020,222(1):79.e1-79.e9. doi: 10.1016/j.ajog.2019.07.025.
[20]	Proctor LK, Kfouri J, Hiersch L, et al. Association between hypertensive disorders and fetal growth restriction in twin compared with singleton gestations[J]. Am J Obstet Gynecol, 2019,221(3):251.e1-251.e8. doi: 10.1016/j.ajog.2019.04.022.
[21]	Benschop L, Schalekamp-Timmermans S, Broere-Brown ZA, et al. Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy[J]. Circulation, 2019,139(14):1698-1709. doi: 10.1161/CIRCULATIONAHA.118.036632. doi: 10.1161/CIRCULATIONAHA.118.036632 pmid: 30760000
[22]	Robertson SA. Preventing Preeclampsia by Silencing Soluble Flt-1?[J]. N Engl J Med, 2019,380(11):1080-1082. doi: 10.1056/NEJMcibr1817501. doi: 10.1056/NEJMcibr1817501 pmid: 30865806
[23]	Sulistyowati S, Bachnas MA, Anggraini ND, et al. Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model[J]. J Perinat Med, 2017,45(2):245-251. doi: 10.1515/jpm-2016-0149. doi: 10.1515/jpm-2016-0149 pmid: 27996960

妊娠期高血压疾病与胎儿生长受限的相关性研究

Study on the Association between Hypertensive Disorders Complicating Pregnancy and Fetal Growth Restriction

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价

[1]	侯春艳, 杜秀萍, 王红红, 侯岳洋. 高迁移率族蛋白A2在胎儿生长受限发病机制中的研究进展[J]. 国际妇产科学杂志, 2025, 52(2): 127-131.
[2]	杨洋, 马媛, 陈宥艺, 赵静, 马文娟. 重度子痫前期患者血清外泌体对人正常蜕膜免疫细胞功能的影响[J]. 国际妇产科学杂志, 2025, 52(2): 143-152.
[3]	张永清, 陈正云, 陈路萍, 颜国辉, 陈丹青. 剖宫产术中诊断足月宫角妊娠二例[J]. 国际妇产科学杂志, 2025, 52(2): 153-157.
[4]	邱婉宁, 魏瑗. 单卵双胎妊娠不一致异常的病因学研究进展[J]. 国际妇产科学杂志, 2024, 51(6): 607-610.
[5]	张琦, 王新, 任毅, 刘超, 高慧婕. SLRPs在胎盘发育及妊娠相关疾病中的研究进展[J]. 国际妇产科学杂志, 2024, 51(5): 525-530.
[6]	张岩, 胡梦颖, 王华, 董渠龙. 超声引导下高强度聚焦超声在妇产科疾病中的应用进展[J]. 国际妇产科学杂志, 2024, 51(4): 406-411.
[7]	孟斐, 刘慧强. 不同来源外泌体在子痫前期发病和治疗中的作用[J]. 国际妇产科学杂志, 2024, 51(1): 10-14.
[8]	张永清, 陈丹青. 胎盘源性外泌体在妊娠期免疫调节中的作用[J]. 国际妇产科学杂志, 2024, 51(1): 15-20.
[9]	胡敏慧, 刘瑞霞, 赵蓉, 阴赪宏. 妊娠期亚临床甲状腺功能减退症与妊娠期高血压疾病关系的研究进展[J]. 国际妇产科学杂志, 2023, 50(6): 679-683.
[10]	计恩婷, 许雅绚, 张春仁, 胡敏, 马红霞. 胎盘线粒体功能在妊娠并发症发生机制中作用的研究[J]. 国际妇产科学杂志, 2023, 50(5): 497-501.
[11]	李晶晶, 孙晓彤, 柳婷婷, 李振英, 张一凡, 苏妍. 成纤维细胞生长因子21与妊娠期代谢性疾病的研究进展[J]. 国际妇产科学杂志, 2023, 50(4): 400-404.
[12]	梁结明, 刘国成. 子痫前期发病机制的研究进展[J]. 国际妇产科学杂志, 2023, 50(4): 405-408.
[13]	李书明, 关红琼. 炎症小体NLRP3在子痫前期中的研究进展[J]. 国际妇产科学杂志, 2023, 50(3): 327-331.
[14]	杨俊娟, 张龑. 胎儿生长受限对胎儿脑神经发育的影响[J]. 国际妇产科学杂志, 2022, 49(5): 570-573.
[15]	何豆豆, 孙晓彤, 张慧芳, 张春阳. 不同来源外泌体中微小RNA在子痫前期的研究进展[J]. 国际妇产科学杂志, 2022, 49(4): 426-429.